Your article (Doctors finds a better drug than aspirin in preventing heart attacks, August 31) is of great importance. It is cited a study that suggests the replacement of aspirin, the cornerstone of the anti -platelet treatment for individuals at a significant risk of heart attacks and strokes, with KubidyDochar. However, we must point out that Clubidogrell does not work uniformly across individuals. Although mentioned in Lancet’s postHe was only light in the Guardian article.
CloPidogrel is the radiance. To work, it must be met by liver enzyme that differs in the population due to the differences in the CYP2C19 gene. Most individuals have “natural” or “natural” levels of the enzyme and the Clubidocral works as expected. However, the “medium interlocutor” stimulates Clubidujarel less efficiently and “the poor of the poor” struggles to activate the Clubidosal at all. For these people, Clubidogrel may not provide adequate protection against heart attacks or strokes.
This issue is not an academic: 20 % -30 % of white individuals in the UK are in a pleasant or poor future 50 % -60 %. Imprisoning individual genetic differences may have legal effects. In 2024, Hawaii won Legal lawsuit against Clubidocral Manufacturers To fail to detect the effectiveness and safety of the drug, given that a large percentage of Hawaiian residents are intermediate or poor receptors.
In short, the effectiveness of Clubidogrell is not universal and may expose the “single -drum pronunciation” approach to the harmful harm. Individuals can be tested for genetic variation in the CYP2C19 gene, which allows a dedicated approach. Patients with normal or natural levels of the enzyme can be treated with Clubidocral as a long -term standard, while those that have lower enzyme levels can continue with aspirin, the current standard. This allocated approach may provide better results than those mentioned in the Lancet paper.
Dr. Rooney Ramloganand Dr. Dimitri Gallardiand Dr. Luigi Venetiansand Dr. Abazoub Aquentola Manchester University, Dr. Cinezia Delo Rousseauand Professor Sir Moner Permahid Liverpool University